Record Q1. Stock fell anyway. Four live catalysts the tape is not pricing.
CME just put up the best quarter in its history — revenue +14%, EPS +20%, ADV +22% to a record 36.2M contracts, records in all six asset classes — and the stock fell 3.3% on the print. It now trades below where it was in March. The market is treating CME as a no-growth utility precisely when it is about to become a structurally higher-growth business. 24/7 crypto goes live May 29 (this Friday). Prediction markets — a $30B+ category — clear through CME via DraftKings. Rare earth futures are coming. And you get paid 4% to wait.
The market priced CME as a utility. It's about to become a growth story.
CME just posted the best quarter in its 178-year history — record revenue, record ADV, record open interest, records in every single asset class. And the stock fell on the print. The market sees a mature exchange operator with stale growth. What it's missing: four independent catalysts, any one of which would justify a re-rating, all firing at once between now and year-end.
One catalyst would justify a re-rating. CME has four — and they're all firing in 2026.
The CME bear case has been the same for a decade: mature business, single-digit volume growth, limited optionality. That case was correct until early 2026. It is now stale. Between February and December of this year, CME activates four independent growth vectors — and not one of them is fully reflected in current estimates. The market is anchored to "boring exchange." The reality is "new-era market infrastructure with regulatory moat."
The Four Catalysts — Magnitude & Timing
Catalyst 1 — 24/7 Crypto Goes Live This Friday (May 29)
CME announced in February that crypto futures and options would move to 24/7 trading on May 29, 2026 — five days from now. This is not a small change. CME did $3 trillion of notional volume in crypto derivatives in 2025. Crypto ADV is already up 46% YoY in 2026. The current Friday-close-to-Sunday-open gap is the single biggest reason institutional capital still uses offshore perpetuals on Binance, Bybit, and OKX. CME closing that gap pulls regulated volume away from offshore venues — directly into CME's fee pool. The Street is modeling crypto as a rounding error. It is about to become a real line.
Catalyst 2 — CME Already Clears Prediction Markets
Prediction markets are no longer fringe. Polymarket: $10.57B monthly volume in March. Kalshi: $14.8B monthly in April, valued at $22B. ICE invested $2B in Polymarket. Robinhood generates $25M per quarter from Kalshi. The category is being repriced as "Information Finance." Critically, when DraftKings launched its CFTC-regulated Predictions app across 38 states in December 2025, it partnered with CME Group to clear the trades. CME is the rails — the boring picks-and-shovels play on the entire prediction market boom. Polymarket and Kalshi get the headlines. CME gets the clearing fees regardless of who wins.
Catalyst 3 — Rare Earth Futures (Trump's Favorite Trade)
CME is preparing to launch the world's first rare earth futures contract — likely NdPr (neodymium-praseodymium), the elements behind EV motors, wind turbines, drones, and advanced weapons. China controls 90% of processed rare earths. Trump has backed a $400M stake in MP Materials, a $1.6B stake in USA Rare Earth, a $12B critical minerals stockpile, and a supply agreement with Australia. Western projects can't get financing because there's no way to hedge price risk. CME solves that. The contract creates a Western pricing benchmark independent of China — geopolitically strategic, structurally needed, and ICE is behind in the race. First-mover in a brand-new commodity class.
Catalyst 4 — "Risk Is The New Normal"
CEO Terry Duffy on the Q1 call: "In a world in which risk has become the new normal, 2026 is off to a record-breaking start." This is the structural tailwind nobody wants to underwrite, because forecasting macro chaos feels uncomfortable. But the data is unambiguous: Q1 ADV +22% to a record 36.2M contracts, records in all six asset classes simultaneously. Rates, equities, FX, energy, agriculture, metals. That has never happened before. When the world is uncertain, every CFO, every hedge fund, every commercial enterprise has to hedge more. CME is the toll road they're forced to use.
90% institutional ownership. ICE just paid $2B to validate the category. The "boring" stock is hiding the consensus.
When 90% of a stock is owned by institutions and the largest competitor in the world just deployed $2 billion to copy your strategy, the market is telling you something. CME has zero retail story, zero meme energy, and zero hype premium. What it has instead is the most concentrated institutional ownership in its peer group — and a category that just got validated by a $2B check from its biggest rival.
Tier 1 — The Signals That Matter Most
| Validator | Action | Date |
|---|---|---|
| Intercontinental Exchange (ICE) | $2B invested in Polymarket. CME's direct competitor paid up to validate prediction markets. CME already clears DraftKings Predictions. ICE is playing catch-up. | 2025-2026 |
| Vanguard Group | 27.0M shares · 7.45% stake. Largest single holder. Passive index buying = institutional benchmark gravity. | Q1 2026 |
| BlackRock + State Street | Combined top-3 institutional holders. Total institutional ownership: 87.75-90.08%. Effectively float-constrained. | Ongoing |
| Terry Duffy (CEO) | Employment contract extended through Dec 31, 2026. "In a world where risk is the new normal, 2026 is off to a record-breaking start." Decade-plus pattern of capital discipline. | Q1 2026 call |
| Rothschild & Co Redburn | Price target raised to $333 (from $300). Neutral rating — but the lift signals model revisions coming. | Feb 2026 |
| DraftKings (DKNG) | Chose CME as clearing partner for its CFTC-regulated Predictions app across 38 states. CME wins the rails play in prediction markets. | Dec 2025 |
| Sell-side consensus | 13 analysts: Buy rating. Average target $307. Range supportive at current $287 level. Coverage is thin on growth optionality. | May 2026 |
Tier 2 — The Capital Return Signal
CME returned ~$4.0 billion to shareholders in 2025 through a combination of the $1.30 quarterly dividend (raised from $1.25 in February) and a $6.15 annual variable dividend declared from 2025 results — a 4.2% total yield based on the average 2025 closing price. The variable dividend is the tell: CME pays out essentially all excess free cash flow each year because management has nothing more accretive to do internally. That is the signal of a fully optimized franchise. Zero capex needs, regulatory moat, monopoly-like market structure in core products — the cash just falls out.
The ICE Read-Through
The single most important data point on this page: Intercontinental Exchange — the operator of the NYSE, CME's biggest exchange-operator rival, and the most sophisticated capital allocator in the exchange space — paid $2 billion for a stake in Polymarket. ICE does not do speculative bets. ICE buys infrastructure. When ICE deploys $2B, it is telling the market that prediction markets are the next major exchange-adjacent revenue line. CME doesn't need to make that bet — CME is already inside the prediction market value chain via DraftKings, with zero capital outlay. If ICE is right about the category, CME wins by default. If ICE is wrong, CME is unaffected. Asymmetric.
The world's largest derivatives marketplace. 178 years of being unkillable.
CME Group Inc. (NASDAQ: CME). Headquartered in Chicago. Traces its lineage to 1848 (CBOT). Operates four Designated Contract Markets — CME, CBOT, NYMEX, and COMEX — spanning interest rates, equity indices, FX, energy, agricultural commodities, and metals. Plus CME Clearing (central counterparty for nearly every futures trade in the U.S.), CME Globex (electronic trading), and CME DataMine (market data). Approximately 3,500 employees. ~361M shares outstanding. Market cap ~$105B.
The Five Revenue Engines
| Engine | What It Is | Why It Matters |
|---|---|---|
| Clearing & Transaction Fees | Per-contract fees on every futures/options trade | ~80% of revenue · pure operating leverage on volume |
| Market Data Services | Real-time + historical data licensing | +15% in Q1 2026 · sticky, subscription-like |
| CME Clearing | Central counterparty for cleared derivatives | Regulatory moat · banks legally required to clear |
| Co-Location & Tech | Premium server space in CME data centers | HFT firms pay up to be physically closest |
| Globex Platform | Electronic trading engine | Where 90%+ of CME volume executes |
The Regulatory Moat Nobody Talks About
CME is not a typical business. It is a Designated Contract Market (DCM) and a Derivatives Clearing Organization (DCO) — both regulated by the CFTC. The barriers to entry are not just capital, brand, or network effects. They are legal. To compete with CME's eurodollar/SOFR futures franchise, a new entrant would need CFTC DCM authorization, DCO registration, regulatory capital, multi-year examiner relationships, and the technical infrastructure for nanosecond-latency matching — and even then, banks would still need to migrate liquidity, which they will not do without an incentive that destroys the new entrant's economics. This is why CME's 70%+ share in rates futures has been stable for two decades.
The Business Model In One Sentence
CME runs a toll road. Every futures contract traded in the U.S. on an exchange essentially has a CME-charged fee attached to it. The toll road requires almost no maintenance capex, no inventory, no working capital. 62% net margins. Capital-light. Cash-generative. The only question is volume — and volume is structurally rising because the world is structurally more uncertain than it used to be.
Recent Strategic Moves
February 2026: Launched futures for Cardano, Chainlink, Stellar (altcoin expansion). February 2026: Declared $6.15 variable dividend + raised regular dividend to $1.30/qtr. February 2026: Working on first-ever rare earth (NdPr) futures contract. April 2026: ESMA recognized CME under the new EU regime. April 30, 2026: Launched new cross-margining services for offsetting transactions. May 29, 2026: 24/7 crypto futures and options go live on Globex.
Record quarter. Stock fell anyway. That's the inefficiency.
Q1 2026 Results (Reported April 22)
| Metric | Q1 2026 | Δ YoY |
|---|---|---|
| Revenue | $1.9B (record) | +14% |
| Adjusted Net Income | $1.2B | +20% |
| Adjusted Diluted EPS | $3.36 (beat $3.31) | +20% |
| Average Daily Volume (ADV) | 36.2M contracts (record) | +22% |
| Clearing & Transaction Revenue | Up 15% | +15% |
| Market Data Revenue | Up 15% | +15% |
| Net Margin | 62.45% | Best-in-class |
| Records Set | All 6 asset classes | First time in company history |
The Valuation Math
CME trades at forward P/E ~24, EV/Revenue ~15-16x, net margin 62%. Comparable best-in-class exchange operators trade in similar bands (ICE 22x, CBOE 22x, NDAQ 25x), so on a peer-relative basis CME is fairly priced. The mispricing is not the multiple. It is the embedded growth rate in those estimates. Sell-side currently models 5-7% volume growth. Q1 ADV was +22%. If 2026 prints anywhere near +15% volume with margin held flat, EPS expands meaningfully — and the same 24x multiple on a higher EPS produces a higher stock price without any re-rating required.
Capital Return Profile
| Item | 2025 | 2026 (Run-rate) |
|---|---|---|
| Quarterly Dividend | $1.25 | $1.30 (raised Feb) |
| Annual Variable Dividend | $6.15 ($2.2B total) | Set annually from prior-year FCF |
| Total 2025 Distributions | ~$4.0B | 4.2% total yield on avg price |
| Forward Dividend Yield | ~1.8% | ~4.0% with variable |
Analyst Coverage
| Firm | Rating | PT | Upside |
|---|---|---|---|
| Rothschild & Co Redburn | Neutral | $333 | +16% |
| Consensus (13 analysts) | Buy | $307 | +7% |
| Morningstar Fair Value | — | $289 | Flat |
Coverage is structurally cautious because most exchange-sector analysts have never modeled a growth quarter from CME. The Street is anchored to the historic 5-7% volume range. Q1's +22% ADV print is the data point that breaks that anchor. Estimate revisions and price target lifts typically follow with a one to two quarter lag.
Trade ideas like this, before they hit the timeline.
Join Discord →A monopoly inside a duopoly inside an oligopoly. And the rivals just validated CME's strategy.
Most analyses describe CME as competing in a four-way exchange operator race against ICE, Nasdaq, and CBOE. That framing is wrong at the product level. CME is essentially unchallenged in the asset classes where it dominates — and rivals have effectively conceded the futures space, choosing instead to compete in cash equities (NDAQ), commodities + data (ICE), and options (CBOE).
The Three Competitive Dynamics That Matter
ICE is the only real strategic threat — and ICE is choosing not to compete in CME's core. Instead, ICE is doubling down on the energy + soft commodity franchise it inherited from NYBOT, the data business it built post-NYSE acquisition, and now prediction markets (the $2B Polymarket bet). This is a tell. If ICE saw a path to dislodging CME's rates / equity index / FX dominance, it would have taken it years ago. It hasn't because it can't. Nasdaq (NDAQ) is now primarily a fintech-software company (Adenza acquisition, market tech, AML/surveillance). Less than 30% of NDAQ revenue is exchange-related. Not a real competitor to CME futures. CBOE is an options house. Strong in VIX and SPX options. Does not clear CME's products.
The Prediction Market Race — CME Already Won The Quiet Way
The most underappreciated competitive dynamic in 2026: CME doesn't need to buy a prediction market platform because it is already inside the value chain. DraftKings Predictions clears through CME. Every retail prediction-market trade routed through that channel generates CME clearing revenue. ICE had to deploy $2B to get equivalent exposure. CME got it for free. That's the asymmetry.
The Crypto Race — Regulation Is The Moat
Offshore exchanges (Binance, Bybit, OKX, Hyperliquid) have 24/7 trading and lower fees. But they are not CFTC-regulated. Institutional capital — pension funds, endowments, registered investment advisors — cannot legally use them. CME running 24/7 starting May 29 means institutions get the always-on hedging they need without taking offshore counterparty risk. Coinbase has Bitcoin/ETH futures via CFE but lacks the institutional rails CME has spent two decades building. The bigger crypto becomes as an institutional asset class, the more CME wins.
Records across the board. Consensus still anchored to "boring."
Bull Case
- Record Q1 across every metric. Revenue +14%, EPS +20%, ADV +22% to record 36.2M contracts. Records in all 6 asset classes simultaneously — first time ever.
- 24/7 crypto launches May 29. Closes the offshore competitive gap. $3T notional in 2025 with crypto ADV already +46% YoY in 2026.
- Prediction markets via DraftKings clear through CME. $30B+ category captured with zero capex.
- Rare earth futures coming. First-mover in geopolitically strategic new commodity class. Trump-aligned thematic.
- $4B returned in 2025 (4.2% total yield). $1.30 quarterly + $6.15 variable. Pay you to wait.
- 62% net margins · 90% institutional ownership. Best-in-class capital efficiency. Float effectively constrained.
- CFTC regulatory moat. Two decades of stable 70%+ market share in core franchises. Effectively unkillable.
- "Risk is the new normal" macro tailwind. Trade war, rates, geopolitics all drive hedging volumes.
Bear Case
- Stock fell 3.3% on record Q1. Buyer fatigue at valuation. Market may not re-rate even on continued beats.
- Trading at ~24x forward P/E. Premium to long-run average. Not statistically cheap.
- Volume sensitivity is a two-way sword. If macro volatility collapses, Q2/Q3 ADV can mean-revert hard.
- Mostly transactional business. Unlike NDAQ or ICE which have built recurring data/software revenue, CME stays cyclical.
- Prediction markets are still small. DraftKings Predictions revenue contribution to CME likely <1% near-term.
- 24/7 crypto adds opex risk. Real-time staffing, settlement, surveillance costs scale up.
- Variable dividend is variable. Cushion shrinks in a down year — direct hit to total yield narrative.
- Democratic CFTC pushback on prediction markets. Regulatory tail risk to the prediction market thesis.
Pay you to wait. Asymmetric upside if any catalyst lands.
Position Structure
This is a core-position long, not a high-conviction option trade. CME is too liquid and too low-vol for cheap LEAPs to create meaningful asymmetry — implied vols sit in the high teens. The yield is the structural alpha. Buy common stock, collect the $1.30 quarterly, and bank the ~$6 variable in Q1 2027. For traders who want a small option overlay, Jan 2027 $300C or Jan 2028 $320C work as a tactical add — but the equity is the trade.
Catalyst Calendar
| Catalyst | Date | Impact |
|---|---|---|
| 24/7 Crypto Goes Live | May 29, 2026 | This Friday. Watch crypto ADV print in June. |
| June 2026 Monthly Volume Report | Early July 2026 | First print showing 24/7 contribution |
| Q2 2026 Earnings | Late July 2026 | The decisive print. Confirms or breaks Q1 trajectory. |
| Ex-Dividend Date | Jun 9, 2026 | $1.30/share quarterly |
| Q3 2026 Earnings | October 2026 | Crypto + prediction market revenue contribution visible |
| Rare Earth Futures Listing | H2 2026 (expected) | First-mover thematic catalyst |
| Q4 2025 + Annual Variable Div Declaration | February 2027 | Sets the next variable dividend payment |
Best margins. Highest yield. The only one with crypto + prediction market exposure built in.
| Ticker | Mkt Cap | Fwd P/E | Net Margin | Div Yield | Growth Hook |
|---|---|---|---|---|---|
| CME | $105B | 24x | 62% | ~4.0% | 24/7 crypto · prediction markets · rare earths |
| ICE | ~$105B | ~22x | ~32% | ~1.0% | Polymarket $2B bet · mortgage tech · data |
| NDAQ | ~$54B | ~25x | ~17% | ~1.2% | Adenza fintech software · AML / surveillance |
| CBOE | ~$26B | ~22x | ~30% | ~1.0% | SPX / VIX options · data licensing |
| COIN | ~$68B | ~28x | ~22% | 0% | Spot crypto · staking · derivatives via CFE |
| HOOD | ~$88B | ~38x | ~25% | 0% | Kalshi partnership ($25M/qtr) · retail option flow |
The Three Comps That Matter
CME vs ICE: Same market cap, similar P/E (24x vs 22x). But CME has nearly 2x the net margin (62% vs 32%) and 4x the yield (4.0% vs 1.0%). ICE just paid $2B for Polymarket exposure that CME got for free via DraftKings. If ICE deserves a 22x multiple, CME deserves more. CME vs COIN: Both crypto-derivatives exposure plays. COIN at 28x P/E with 22% margins and zero dividend; CME at 24x with 62% margins and 4% yield. CME is the boring-uncle crypto trade — same beta, half the risk. CME vs HOOD: Both prediction-market exposed. HOOD at 38x P/E with no dividend; CME at 24x with 4% yield. HOOD is the high-beta narrative trade; CME is the rails. Different risk/reward profiles for different parts of the book.
Long CME. Core position. Collect the yield. Let the catalysts compound.
CME just put up a record quarter with records in every single asset class — and the stock fell. That's the inefficiency. The Street is modeling a mature 5-7% volume grower. Reality: Q1 ADV +22% with four independent growth vectors firing in 2026 — 24/7 crypto live this Friday, prediction markets already clearing through CME via DraftKings, rare earth futures coming, and "risk is the new normal" macro driving record hedging. You get 62% net margins, 4% total yield, a CFTC regulatory moat that has held for two decades, and 90% institutional ownership. This is the boring trade nobody is talking about because everyone is busy fighting over Polymarket and Kalshi headlines. The rails wins regardless of which platform tops the volume table. Pay you to wait. Re-rate when the catalysts land.